Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | GJB2 | P29033 | 4/20 | 0.33 |
| ▸ | FGF1 | P05230 | 3/20 | 0.32 |
| ▸ | FGF2 | P09038 | 3/20 | 0.32 |
| ▸ | VEGFA | P15692 | 3/20 | 0.32 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371589 | 1.00 | GBA1 (0.33) | GBA1GJB2FGF1FGF2VEGFA | |
| SCHEMBL12371590 | 0.79 | TLR4 (0.39) | FGF1FGF2HPSE | |
| SCHEMBL13296761 | 0.79 | TLR4 (0.39) | FGF1FGF2HPSE | |
| SCHEMBL12371588 | 0.79 | — | — | |
| SCHEMBL13296754 | 0.79 | — | — | |
| SCHEMBL12396681 | 0.74 | GBA1 (0.48) | GBA1GJB2 | |
| SCHEMBL12560722 | 0.74 | GBA1 (0.48) | GBA1GJB2 | |
| SCHEMBL12371584 | 0.74 | GBA1 (0.48) | GBA1GJB2 | |
| SCHEMBL13315218 | 0.74 | GBA1 (0.48) | GBA1GJB2 | |
| SCHEMBL12371548 | 0.74 | GBA1 (0.34) | GBA1GJB2FGF1FGF2VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737129-B2 | Substituted liposaccharides useful in the treatment and prevention of endotoxemia | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20080214802-A1 | Substituted Liposaccharides Useful in the Treatment and Prevention of Endotoxemia | EISAI CO., LTD. (JP) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214802-A1 | Substituted Liposaccharides Useful in the Treatment and Prevention of Endotoxemia | LIPG, FUT6, UGCG | GBA1 195/4885GJB2 4728/4885FGF1 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.